


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-10.35%
+3.55%
+5.28%
-2.31%
MRNA
Moderna
$51.88
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value
MRNA Price Performance
$32.29 (+60.67%)
$26.66 (+94.60%)
$24.47 (+112.01%)
$33.61 (+54.36%)
MRNA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
MRNA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MRNA Street Sentiment is bullish and have positive views on the near-term outlook
MRNA has Medium risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
What is MRNA current stock price?
What are MRNA stock strengths?
What is MRNA Risk Level?
What is MRNA market cap and volume?
What is MRNA current Stock IQ?
Should I buy MRNA stock right now?
Is MRNA a Strong Buy right now?
What does a 'Strong Buy' rating mean for MRNA?
What does a 'Strong Sell' rating mean for MRNA?
What factors influence MRNA's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-10.35%
+3.55%
+5.28%
-2.31%
MRNA
Moderna
Current Price
$51.88
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Trading below its fair value

MRNA Price Performance
$32.29 (+60.67%)
$26.66 (+94.60%)
$24.47 (+112.01%)
$33.61 (+54.36%)
MRNA Analysts Opinion
MRNA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
MRNA Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
MRNA Street Sentiment is bullish and have positive views on the near-term outlook
MRNA has Medium risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Jan 06, 2026
Downgrade
Neutral
UBS
Nov 22, 2025
Reiterate
Overweight
Piper Sandler
Oct 24, 2025
Reiterate
Buy
UBS
Oct 23, 2025
Reiterate
Neutral
Citigroup
Oct 20, 2025
Reiterate
Hold
Needham
MRNA Stock IQ
MRNA Latest Analysis
Moderna extends YTD rally to hit 52-week high.
Today
Moderna shares soar through the week momentum data points toward caution.
Today
Moderna (MRNA) Touches 52-Week High on Strong Clinical Results. We recently published 10 Big Names Leaving Wall Street Behind. 7 Are Hitting Record Highs. Moderna Inc. (NASDAQ:MRNA) was one of the worst performers on Wednesday. Moderna surged to a new 52-week high of $50 on Wednesday a 16 percent jump as investors took heart from the strong results of its clinical study for Intismeran [….]
Today
Stock Market Today: S&P 500 Dow Jones Futures Rise As Trump Scales Down EU Tariff Threats—Microsoft Moderna Intel In Focus. United States stock futures rose on Thursday following Wednesday’.s gains. Futures of major benchmark indices were higher.The indices settled higher on Wednesday gaining more than 1% during the session after President withdrew his latest round of tariff threats. He stated that planned tariffs on European Union countries will no longer take effect following what he desc
Today
Why Moderna Stock Surged Today. Key PointsModernas and Mercks partnership could help to advance cancer care.
Today
Moderna Stock Skyrockets To 52-Week High: Whats Behind The Surge?. MRNA).Moderna shares are testing new highs. Moderna and ) released five‑year median follow‑up data from the Phase 2b KEYNOTE‑942/mRNA‑4157‑P201 trial which is testing intismeran autogene (mRNA‑4157) — an individualized mRNA‑based neoantigen therapy — when used alongside Merck'.s KEYTRUDA in patients with high‑risk melanoma who have undergone complete tumor removal.According to the update adding intismeran autogene to KEYTRUDA
Wed Jan 21, 2026
Modernas Options: A Look at What the Big Money is Thinking. Investors with a lot of money to spend have taken a ish stance on MRNA).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals we don'.t know. But when something this big happens with MRNA it often means somebody knows something is about to happen.So how do we know what these investo
Tue Jan 20, 2026
Arbutus Biopharma Shares Fall 19% On European Patent Revocation . (RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents EP2279254 after years of opposition proceedings initiated by Moderna and Merck affiliates.
Fri Jan 16, 2026
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?. MRNA shares rise after upbeat 2025 sales stronger cash outlook and detailed 2026 guidance alongside multiple pipeline milestones.
Thu Jan 15, 2026
Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results.
Wed Jan 14, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
MRNA Stock trends
MRNA Stock performance
MRNA Stock analysis
MRNA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.